Benefits
Skin Redness Reduction
Pharmactive 60-day consumer study (50 adults aged 40-60) at 300 mg/day showed 74% reduction in skin redness. Useful for inflammatory skin conditions, sensitivity, rosacea-adjacent concerns.
Itching Reduction
Same study: 76% reduction in itching. Relevant for: eczema-adjacent conditions, dry skin itching, sensitive skin.
Skin Tightness Reduction
72% reduction in skin tightness sensation. Improves overall skin comfort.
Hydration and Skin Quality (~72% improvement)
Improvements in skin hydration and overall quality. Beauty-from-within mechanism complementing topical interventions.
Strong User Satisfaction (80% Visible Effects)
80% noticed visible effects; 78% said it worked fast and would recommend it. Clinically meaningful real-world satisfaction.
Multiple Inflammatory Pathway Inhibition
Activity via inhibition of NF-κB, COX-2, and PGE₂ — foundational anti-inflammatory pathways. Strong antioxidant protection from polyphenol fraction.
Mechanism of action
NF-κB Pathway Inhibition
NF-κB is master inflammatory transcription factor; Xorialyc compounds inhibit NF-κB activation — reduces downstream inflammatory gene expression in skin cells.
COX-2 Inhibition
COX-2 produces inflammatory prostaglandins; Xorialyc compounds inhibit COX-2 — reduces inflammatory prostaglandin synthesis. Same target as NSAIDs.
PGE₂ Reduction
Prostaglandin E2 (PGE₂) drives inflammatory skin reactions; Xorialyc reduces PGE₂ formation.
Luteolin and Quercetin Bioactivity
Luteolin is potent anti-inflammatory flavonoid; quercetin has documented anti-inflammatory/antioxidant effects; Xorialyc concentrates these compounds for skin applications.
Ortho-Diphenol Antioxidant Activity
Ortho-diphenols (catechol-type structures including hydroxytyrosol-related compounds) provide potent antioxidant activity protecting skin from oxidative damage.
Clinical trials
60-day consumer study of Xorialyc 300 mg/day in 50 adults aged 40-60.
50 adults aged 40-60.
74% redness reduction, 76% itching reduction, 72% tightness reduction, ~72% hydration/skin quality improvement; 80% noticed visible effects; 78% would recommend.
Multiple studies of olive polyphenols on inflammatory pathways including NF-κB, COX-2, PGE₂.
Cell, animal, and human studies.
Confirmed inhibition of NF-κB, COX-2, PGE₂; established anti-inflammatory mechanism for skin and other inflammatory applications.
About this ingredient
XORIALYC® is a NEXT-GENERATION OLIVE LEAF EXTRACT developed by PHARMACTIVE BIOTECH PRODUCTS (Spain) — designed specifically for SKIN INFLAMMATION and skin quality applications. POSITIONING: 'natural relief for skin inflammation.' RELATIONSHIP TO OTHER PHARMACTIVE OLIVE PRODUCTS: ISENOLIC® (cold/flu prevention), OLIVACTIVE® (general immune), XORIALYC® (skin inflammation) — three different positionings of olive leaf with distinct standardization for specific applications.
KEY ACTIVES: LUTEOLIN, QUERCETIN, ORTHO-DIPHENOLS, OLEUROPEIN, hydroxytyrosol — concentrated standardization for skin applications.
KEY MECHANISTIC TARGETS: NF-κB, COX-2, PGE₂ inhibition + antioxidant protection.
EVIDENCE-BASED USES: (1) SKIN REDNESS reduction (74% in 60-day study); (2) ITCHING reduction (76%); (3) SKIN TIGHTNESS reduction (72%); (4) HYDRATION and skin quality improvement (~72%); (5) Anti-inflammatory skin support; (6) Antioxidant skin protection; (7) Beauty-from-within applications.
CRITICAL CAUTIONS: (1) DOSE — 300 mg/day per Pharmactive 60-day clinical study; (2) DURATION — skin effects build over 60 days in clinical study; not immediate; (3) DIAGNOSED SKIN CONDITIONS — for diagnosed eczema, psoriasis, rosacea, dermatitis: consult dermatologist; Xorialyc may be adjunct; (4) PREGNANCY/LACTATION — culinary olive use safe; concentrated extract supplementation limited safety data; consult; (5) CONSUMER STUDY DESIGN — Pharmactive's 60-day consumer study (vs RCT) provides real-world satisfaction evidence; less methodologically rigorous than RCT; (6) XORIALYC vs TOPICAL ANTI-INFLAMMATORIES — oral supplementation provides systemic effect on skin; topical interventions (corticosteroids, calcineurin inhibitors, ceramides) provide local effect; complementary approaches; (7) UV PROTECTION — Xorialyc does NOT replace sunscreen; sun protection remains primary photoprotection; (8) SKIN INFLAMMATION COMPREHENSIVE APPROACH — gentle skincare, identification of triggers (allergens, irritants), moisturization, possibly prescription topicals for severe cases, supplements one tool; (9) XORIALYC vs DERMANIA (Saanroo) vs ASTAXANTHIN — different mechanisms for skin support; Xorialyc emphasis on inflammation; complementary; (10) FOR INFLAMMATORY SKIN CONDITIONS — beauty-from-within Xorialyc reasonable adjunct alongside dermatologist-guided care for severe conditions; (11) BRAND VERIFICATION — Xorialyc® is Pharmactive trademark; specific clinical evidence on this 300 mg/day standardized form; (12) Strong real-world satisfaction evidence from 60-day consumer study; one of the more evidence-based oral skin anti-inflammatory ingredients.